Decellularized Femoral Artery Allograft (Nexeon AVX) Prospective Registry (NCT05880537)
Safety, Efficacy, & Use of Decellularized Femoral Artery Allograft for Arteriovenous Access for Hemodialysis: A Multi-center Prospective Registry Study
🩺 Plain-English Summary (8th-Grade Level)
Post market registry to assess the safety and efficacy of a novel decellularized human femoral artery allograft (Nexeon AVX Decellularized Femoral Artery,
Who can join: Review the eligibility criteria below.
Location: Infirmary Heath — Mobile, Alabama
Age range: 18 Years
🧪 Interventions in This Study
- Nexeon Arterial Venous Allograft (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (4 Sites)
- Infirmary Heath — Mobile, Alabama
- Olive View - UCLA Medical Center — Sylmar, California
- Harbor-UCLA Medical Center — Torrance, California
- Sentara Norfolk General Hospital — Norfolk, Virginia
📞 Contact the Study Coordinator
Phone: (757) 609-4378
Email: kimberly_dorsch@lifenethealth.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in End-Stage Renal Disease
Explore by condition: All End-Stage Renal Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.